| Name | 5-LOX-IN-2 |
| Description | 5-LOx-in-2 is a 5-lipoxygenase inhibitor (5-LOX) with an IC50 value of 0.33 μM. 5-lox-in-2 inhibits 5-LOX action IN a dose-dependent manner. 5-LOX-IN-2 can reduce the cell activity of kidney cancer cells and induce apoptosis, and can be used in cancer research. |
| In vitro | 5-LOX-IN-2 at a concentration of 0-100 μM, after 4 days of action, reduced the activity of renal cancer cells (RCC4, RCC10, 786.0 cells) and showed higher selectivity for RCC4 and 786.0 cells deficient in the von Hippel-Lindau (VHL) tumor suppressor gene. 5-LOX-IN-2 at a concentration of 0-10 μM, after 24 hours of action, was capable of increasing the expression of LC3B and p62, and inducing apoptosis through the activation of the caspase-3 pathway. concentration and after 24 hours of action, it was able to increase the expression of LC3B and p62, block the autophagic flow in RCC4 cells, and induce apoptosis by activating the caspase-3 pathway. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.03 mM), Sonication is recommended.
DMSO : 50 mg/mL (175.86 mM), Sonication is recommended.
|
| Keywords | Apoptosis | 5-LOX-IN-2 | 5LOXIN2 | 5-LOX |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Inhibitor Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
